Source comparison
BPC-157 vs Wolverine Stack: Research Protocol Comparison
Primary Mechanism VEGF-driven angiogenesis, localized collagen synthesis Multi-pathway: angiogenesis + actin regulation + systemic IGF-1 elevation Wolverine addresses more pathways but adds complexity Typical Dosing Frequency 200–500 mcg daily (subcutaneous or
This comparison does not assign a generated winner or score.
- Primary Mechanism
- VEGF-driven angiogenesis, localized collagen synthesis
- Multi-pathway: angiogenesis + actin regulation + systemic IGF-1 elevation
- Wolverine addresses more pathways but adds complexity
- Typical Dosing Frequency
- 200–500 mcg daily (subcutaneous or intra-site)
- BPC-157 daily, TB-500 twice weekly, GH secretagogue 1–2x daily
- Wolverine requires managing three separate injection schedules
- Reconstitution Stability
- 28 days refrigerated after mixing with bacteriostatic water
- BPC: 28 days, TB-500: 30–45 days, GH secretagogue: 14–21 days
- Wolverine demands stricter expiration tracking
- Human Clinical Evidence
- Limited (mostly animal models, case reports)
- Very limited (no published trials of the combined stack)
- Both lack Phase 3 human trial data
- Cost Per 4-Week Cycle
- Approximately $80–120 for standalone BPC-157
- Approximately $200–350 for all three peptides combined
- Wolverine costs 2.5–3× more per cycle
- Ideal Research Application
- Localized soft tissue injury (tendon, ligament, gut lining repair)
- Multi-site trauma, post-surgical recovery, muscle-tendon unit healing
- Choose based on injury complexity, not assumed superiority